{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:31:15Z","timestamp":1790242275225,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T00:00:00Z","timestamp":1429142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T00:00:00Z","timestamp":1429142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1038\/gt.2015.13","type":"journal-article","created":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T12:06:59Z","timestamp":1429186019000},"page":"476-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus"],"prefix":"10.1038","volume":"22","author":[{"given":"J","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Alusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Bhakta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-7586","authenticated-orcid":false,"given":"I","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"McCart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N R","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2367-6313","authenticated-orcid":false,"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,16]]},"reference":[{"key":"BFgt201513_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/v2010078","volume":"2","author":"HH Wong","year":"2010","unstructured":"Wong HH, Lemoine NR, Wang Y . Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2010; 2: 78\u2013106.","journal-title":"Viruses"},{"key":"BFgt201513_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jnci\/djj111","volume":"98","author":"K Garber","year":"2006","unstructured":"Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98: 298\u2013300.","journal-title":"J Natl Cancer Inst"},{"key":"BFgt201513_CR3","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1038\/sj.onc.1209044","volume":"24","author":"JM Mathis","year":"2005","unstructured":"Mathis JM, Stoff-Khalili MA, Curiel DT . Oncolytic adenoviruses \u2013 selective retargeting to tumor cells. Oncogene 2005; 24: 7775\u20137791.","journal-title":"Oncogene"},{"key":"BFgt201513_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrc2545","volume":"9","author":"DH Kirn","year":"2009","unstructured":"Kirn DH, Thorne SH . Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64\u201371.","journal-title":"Nat Rev Cancer"},{"key":"BFgt201513_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1593\/tlo.12115","volume":"5","author":"GK Friedman","year":"2012","unstructured":"Friedman GK, Haas MC, Kelly VM, Markert JM, Gillespie GY, Cassady KA . Hypoxia moderates gamma(1)34.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary cultures. Transl Oncol 2012; 5: 200\u2013207.","journal-title":"Transl Oncol"},{"key":"BFgt201513_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/sj.gt.3302736","volume":"13","author":"B Shen","year":"2006","unstructured":"Shen B, Bauzon M, Hermiston T . The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Therapy 2006; 13: 986\u2013990.","journal-title":"Gene Therapy"},{"key":"BFgt201513_CR7","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/sj.gt.3302448","volume":"12","author":"B Shen","year":"2005","unstructured":"Shen B, Hermiston T . Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Therapy 2005; 12: 902\u2013910.","journal-title":"Gene Therapy"},{"key":"BFgt201513_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/gt.2009.132","volume":"17","author":"CT Hiley","year":"2010","unstructured":"Hiley CT, Yuan M, Lemoine NR, Wang Y . Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Therapy 2010; 17: 281\u2013287.","journal-title":"Gene Therapy"},{"key":"BFgt201513_CR9","volume-title":"Smallpox and its Eradication","author":"F Fenner","year":"1988","unstructured":"Fenner F, HD AI, Jezek Z, Ladnyi ID . Smallpox and its Eradication. WHO: Geneva, 1988."},{"key":"BFgt201513_CR10","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI32727","volume":"117","author":"SH Thorne","year":"2007","unstructured":"Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007; 117: 3350\u20133358.","journal-title":"J Clin Invest"},{"key":"BFgt201513_CR11","first-page":"8751","volume":"61","author":"JA McCart","year":"2001","unstructured":"McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751\u20138757.","journal-title":"Cancer Res"},{"key":"BFgt201513_CR12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/gt.2009.74","volume":"16","author":"JR Tysome","year":"2009","unstructured":"Tysome JR, Briat A, Alusi G, Cao F, Gao D, Yu J et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther 2009; 16: 1223\u20131233.","journal-title":"Gene Ther"},{"key":"BFgt201513_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1089\/hum.2010.172","volume":"22","author":"JR Tysome","year":"2011","unstructured":"Tysome JR, Wang P, Alusi G, Briat A, Gangeswaran R, Wang J et al. Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer. Hum Gene Ther 2011; 22: 1101\u20131108.","journal-title":"Hum Gene Ther"},{"key":"BFgt201513_CR14","doi-asserted-by":"publisher","first-page":"S665","DOI":"10.1245\/s10434-011-2198-x","volume":"19","author":"D Haddad","year":"2012","unstructured":"Haddad D, Chen N, Zhang Q, Chen CH, Yu YA, Gonzalez L et al. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers. Ann Surg Oncol 2012; 19: S665\u2013S674.","journal-title":"Ann Surg Oncol"},{"key":"BFgt201513_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jsb.2011.03.010","volume":"175","author":"MW Bahar","year":"2011","unstructured":"Bahar MW, Graham SC, Chen RA, Cooray S, Smith GL, Stuart DI et al. How vaccinia virus has evolved to subvert the host immune response. J Struct Biol 2011; 175: 127\u2013134.","journal-title":"J Struct Biol"},{"key":"BFgt201513_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1600-065X.1997.tb01012.x","volume":"159","author":"GL Smith","year":"1997","unstructured":"Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A . Vaccinia virus immune evasion. Immunol Rev 1997; 159: 137\u2013154.","journal-title":"Immunol Rev"},{"key":"BFgt201513_CR17","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1099\/0022-1317-71-11-2761","volume":"71","author":"JD Williamson","year":"1990","unstructured":"Williamson JD, Reith RW, Jeffrey LJ, Arrand JR, Mackett M . Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 1990; 71: 2761\u20132767.","journal-title":"J Gen Virol"},{"key":"BFgt201513_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.gt.3302840","volume":"14","author":"CF Hung","year":"2007","unstructured":"Hung CF, Tsai YC, He L, Coukos G, Fodor I, Qin L et al. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther 2007; 14: 20\u201329.","journal-title":"Gene Ther"},{"key":"BFgt201513_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.cgt.7700075","volume":"7","author":"M Puhlmann","year":"2000","unstructured":"Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7: 66\u201373.","journal-title":"Cancer Gene Ther"},{"key":"BFgt201513_CR20","volume-title":"The diagnosis of smallpox","author":"TF Ricketts","year":"1966","unstructured":"Ricketts TF . The diagnosis of smallpox. U. S. Public Health Service, Division of Foreign Quarantine: Washington, 1966."},{"key":"BFgt201513_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/hum.2005.16.435","volume":"16","author":"E Chang","year":"2005","unstructured":"Chang E, Chalikonda S, Friedl J, Xu H, Phan GQ, Marincola FM et al. Targeting vaccinia to solid tumors with local hyperthermia. Hum Gene Ther 2005; 16: 435\u2013444.","journal-title":"Hum Gene Ther"},{"key":"BFgt201513_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/ENDO:12:1:1","volume":"12","author":"LP Reynolds","year":"2000","unstructured":"Reynolds LP, Grazul-Bilska AT, Redmer DA . Angiogenesis in the corpus luteum. Endocrine 2000; 12: 1\u20139.","journal-title":"Endocrine"},{"key":"BFgt201513_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/icb.1990.46","volume":"68","author":"G Karupiah","year":"1990","unstructured":"Karupiah G, Blanden RV . Anti-asialo-GM1 inhibits vaccinia virus infection of murine ovaries: asialo-GM1 as an additional virus receptor? Immunol Cell Biol 1990; 68: 343\u2013346.","journal-title":"Immunol Cell Biol"},{"key":"BFgt201513_CR24","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/JVI.72.2.1577-1585.1998","volume":"72","author":"CS Chung","year":"1998","unstructured":"Chung CS, Hsiao JC, Chang YS, Chang W . A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 1998; 72: 1577\u20131585.","journal-title":"J Virol"},{"key":"BFgt201513_CR25","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1128\/JVI.74.7.3353-3365.2000","volume":"74","author":"CL Lin","year":"2000","unstructured":"Lin CL, Chung CS, Heine HG, Chang W . Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol 2000; 74: 3353\u20133365.","journal-title":"J Virol"},{"key":"BFgt201513_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/hum.2009.135","volume":"20","author":"RJ Prestwich","year":"2009","unstructured":"Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009; 20: 1119\u20131132.","journal-title":"Hum Gene Ther"},{"key":"BFgt201513_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri1936","volume":"6","author":"L Zitvogel","year":"2006","unstructured":"Zitvogel L, Tesniere A, Kroemer G . Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715\u2013727.","journal-title":"Nat Rev Immunol"},{"key":"BFgt201513_CR28","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1084\/jem.170.6.2081","volume":"170","author":"DF Fiorentino","year":"1989","unstructured":"Fiorentino DF, Bond MW, Mosmann TR . Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081\u20132095.","journal-title":"J Exp Med"},{"key":"BFgt201513_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2008.00635.x","volume":"223","author":"A O'Garra","year":"2008","unstructured":"O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C . Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008; 223: 114\u2013131.","journal-title":"Immunol Rev"},{"key":"BFgt201513_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/sj.cgt.7701104","volume":"15","author":"F Tanaka","year":"2008","unstructured":"Tanaka F, Tominaga K, Shiota M, Ochi M, Kuwamura H, Tanigawa T et al. Interleukin-10 gene transfer to peritoneal mesothelial cells suppresses peritoneal dissemination of gastric cancer cells due to a persistently high concentration in the peritoneal cavity. Cancer Gene Ther 2008; 15: 51\u201359.","journal-title":"Cancer Gene Ther"},{"key":"BFgt201513_CR31","first-page":"5091","volume":"63","author":"T Kohno","year":"2003","unstructured":"Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 2003; 63: 5091\u20135094.","journal-title":"Cancer Res"},{"key":"BFgt201513_CR32","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1182\/blood.V96.7.2568","volume":"96","author":"L Cervenak","year":"2000","unstructured":"Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson JL et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 2000; 96: 2568\u20132573.","journal-title":"Blood"},{"key":"BFgt201513_CR33","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/107999099313532","volume":"19","author":"S Huang","year":"1999","unstructured":"Huang S, Ullrich SE, Bar-Eli M . Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 1999; 19: 697\u2013703.","journal-title":"J Interferon Cytokine Res"},{"key":"BFgt201513_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000236329","volume":"99","author":"H Spits","year":"1992","unstructured":"Spits H . de Waal Malefyt R. Functional characterization of human IL-10. Int Arch Allergy Immunol 1992; 99: 8\u201315.","journal-title":"Int Arch Allergy Immunol"},{"key":"BFgt201513_CR35","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E","volume":"71","author":"FY Yue","year":"1997","unstructured":"Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71: 630\u2013637.","journal-title":"Int J Cancer"},{"key":"BFgt201513_CR36","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1084\/jem.180.6.2371","volume":"180","author":"M Matsuda","year":"1994","unstructured":"Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180: 2371\u20132376.","journal-title":"J Exp Med"},{"key":"BFgt201513_CR37","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1182\/blood.V85.12.3423.bloodjournal85123423","volume":"85","author":"R Masood","year":"1995","unstructured":"Masood R, Zhang Y, Bond MW, Scadden DT, Moudgil T, Law RE et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 1995; 85: 3423\u20133430.","journal-title":"Blood"},{"key":"BFgt201513_CR38","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V88.10.3972.bloodjournal88103972","volume":"88","author":"ZJ Gu","year":"1996","unstructured":"Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996; 88: 3972\u20133986.","journal-title":"Blood"},{"key":"BFgt201513_CR39","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1172\/JCI31422","volume":"117","author":"A Sica","year":"2007","unstructured":"Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155\u20131166.","journal-title":"J Clin Invest"},{"key":"BFgt201513_CR40","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","volume":"42","author":"A Sica","year":"2006","unstructured":"Sica A, Schioppa T, Mantovani A, Allavena P . Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717\u2013727.","journal-title":"Eur J Cancer"},{"key":"BFgt201513_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-0-387-69116-9_5","volume":"604","author":"C Porta","year":"2007","unstructured":"Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, Sica A . Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol 2007; 604: 67\u201386.","journal-title":"Adv Exp Med Biol"},{"key":"BFgt201513_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0165-2478(98)00125-4","volume":"65","author":"GL Smith","year":"1999","unstructured":"Smith GL . Vaccinia virus immune evasion. Immunol Lett 1999; 65: 55\u201362.","journal-title":"Immunol Lett"},{"key":"BFgt201513_CR43","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1099\/vir.0.79980-0","volume":"85","author":"NW Bartlett","year":"2004","unstructured":"Bartlett NW, Dumoutier L, Renauld JC, Kotenko SV, McVey CE, Lee HJ et al. A new member of the interleukin 10-related cytokine family encoded by a poxvirus. J Gen Virol 2004; 85: 1401\u20131412.","journal-title":"J Gen Virol"},{"key":"BFgt201513_CR44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2144\/01313st07","volume":"31","author":"TM Timiryasova","year":"2001","unstructured":"Timiryasova TM, Chen B, Fodor N, Fodor I . Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper. Biotechniques 2001; 31: 538\u2013540.","journal-title":"Biotechniques"},{"key":"BFgt201513_CR45","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/nbt887","volume":"21","author":"Y Wang","year":"2003","unstructured":"Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003; 21: 1328\u20131335.","journal-title":"Nat Biotechnol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201513","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T09:21:08Z","timestamp":1661246468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,16]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["BFgt201513"],"URL":"https:\/\/doi.org\/10.1038\/gt.2015.13","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,16]]},"assertion":[{"value":"26 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}